Chimerism does not predict for outcome after alemtuzumab based conditioning

Bone Marrow Transplant. 2007 Jul;40(2):181. doi: 10.1038/sj.bmt.1705707. Epub 2007 May 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Graft vs Host Disease / prevention & control
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / therapy
  • Humans
  • Stem Cell Transplantation
  • Transplantation Chimera / immunology*
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Alemtuzumab